Can obesity medications replace metabolic and bariatric surgery? A comprehensive review
-
Ko TYL, Cohen RV, Le Roux CW.
Can obesity medications replace metabolic and bariatric surgery? A comprehensive review Ko TYL, Cohen RV, Le Roux CW.
Publication Category: Medications
Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5
- Galindo RJ, Aronne LJ, Horn DB, Miras AD, Dunn JP, Cao D, Lee CJ, Karanikas CA, Heine RJ, Falcon BL, Dimitriadis GK. Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5 J Endocrinol Invest
Suboptimal therapeutic responses associated with semaglutide in type 2 diabetes and obesity: A meta-analysis of randomized controlled trials
- Ko D, Kim DH, Tan FXN, Ho GJK, Chandra R, Xuan ZZ, Jun ETK, Tang NSY, Yang HS, Koh JWH, Danpanichkul P, Dalakoti M, Syn NL, Wijarnpreecha K, Takahashi H, Zheng MH, Nakajima A, Noureddin M, Muthiah M, Le Roux CW, Siddiqui MS, Ng CH. Suboptimal therapeutic responses associated with semaglutide in type 2 diabetes and obesity: A meta-analysis of randomized controlled trials Cell Rep Med
Factors influencing patient preferences for obesity pharmacotherapy: The triangulation of semi-structured interviews, photovoice study and focus group discussions
-
Mondoh A, Contreras F, Craig H, Crotty M, Le Roux CW.
Factors influencing patient preferences for obesity pharmacotherapy: The triangulation of semi-structured interviews, photovoice study and focus group discussions Obes Pillars
Logistics, effectiveness, safety, and accessibility: Factors determining obesity medication patient preferences from a photovoice analysis
-
Mondoh A, Contreras F, Craig H, Crotty M, le Roux CW.
Logistics, effectiveness, safety, and accessibility: Factors determining obesity medication patient preferences from a photovoice analysis Obes Pillars
Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies
-
Alhazmi A, le Roux CW.
Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies Front Endocrinol (Lausanne)
Development of the European Association for the Study of Obesity (EASO) Grade-Based Framework on the Pharmacological Treatment of Obesity: Design and Methodological Aspects
-
McGowan B, Ciudin A, Baker JL, Busetto L, Dicker D, Frühbeck G, Goossens GH, Monami M, Ragghianti B, Sbraccia P, Martinez-Tellez B, Woodward E, Yumuk V.
Development of the European Association for the Study of Obesity (EASO) Grade-Based Framework on the Pharmacological Treatment of Obesity: Design and Methodological Aspects Obes Facts
Optimization of patient and site engagement in the SYNCHRONIZE™ phase 3 clinical trial program for survodutide in obesity through clinical trial simulation
-
Rubino DM, Mooney V, van de Walle V, Baanstra D, Daniëls W, Recaldin C, Nadglowski J.
Optimization of patient and site engagement in the SYNCHRONIZE™ phase 3 clinical trial program for survodutide in obesity through clinical trial simulation Contemp Clin Trials Commun
Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: a 6-month retrospective cohort study
-
le Roux CW, Done N, Brnabic AJM, Zion A, Lipkovich I, Kadziola Z, Dunn JP, Desai U, Kirson N, Dimitriadis GK, Kan H.
Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: a 6-month retrospective cohort study J Endocrinol Invest